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Various enteric, non-fermenter and miscellaneous organisms 1356
TOTAL 6586


















Susceptible Susceptible Susceptible Disc diffusion E test Disc diffusion
Penicillin/Amoxicillin 69% 72% 74% Susceptible Susceptible Susceptible
Cotrimoxazole 59% 56% 55% Co-amoxiclav - 99% 98%
Minocycline,
Tetracycline
45% 59% 58% Clarithromycin - 86% 88%
Nitrofurantoin 94% 91% 96% Cefprozil - 95% 92%
Gentamicin 92% 89% 91% Cefaclor - 76% 88%




93.50% 92% 90% Cotrimoxazole 42% 18% 22%
12% Staphylococci are ORSA/ORSE.
They are susceptible to:-
2003 2004 - 2005 Ciprofloxacin - - 96%
Vancomycin  100% 100% Ofloxacin 93.50% - 96%
Netilmycin  92% 94% Penicillin 63% 52% 68%
Nitrofurantoin  98% 96% Erythromycin 86% - 78%
Nalidixic acid  22% 28% Chloramphenicol 81.50% - 82%
Ciprofloxacin  45% 52% Tetracycline 77% - 72%

















Susceptible Susceptible Susceptible Susceptible Susceptible Susceptible




100% 100% 100% Augmentin 99% 100% 90%
















84% 71% 74% Chloramphenicol 86% - 90%
ENTEROCOCCI Tetracyclines 78% - -
Antibiotic







Ofloxacin 93% - 92%







Augmentin 91.50% 94% 95% SHIGELLAS – 233 S. sonnei S. flexneri S. dysenteriae
High Level Gentamicin 90.50% 82% 80% Antibiotic 82 119 32
High Level
Streptomycin
84% 77% 72% Ampicillin 33% 25% 15%
Ciprofloxacin 81% 79% 82% Cotrimoxazole 26% 26% 10%
Vancomycin (six
resistant isolates seen
so far) in Nairobi
100% 100% 100% Chloramphenicol 70% 85% 100%
Nitrofurantoin 98.50% 97% 95% Ciprofloxacin 100% 100% 100%
Nalidixic Acid 89 74% 72% Ceftriaxone 100% 100% 100%
This data and report is courtesy of Dr. Revathi and the Pathology Department.
ESCHERICHIA COLI KLEBSIELLA PNEMONIAE
Approximately 14% of isolates produce extended spectrum beta
lactamases in 2003, 22% in 2005
Aprroximately 11% are extended spectrum beta lactamase

















Susceptible Susceptible Susceptible Susceptible Susceptible Susceptible
Augmentin 91% 88% 87% Augmentin 88.50% 86% 89%
Gentamicin 85% 86% 88% Gentamicin 90.50% 84% 88%
Amikacin 93% 89% 90% Amikacin 90% 90% 92%
Chloramphenicol 67% 53% 58% Chloramphenicol 55% 61% 64%
Cefuroxime 90.50% 89% 82% Cefuroxime 95% 91% 88%
Ceftazidime 96% 89% 91% Ceftazidime 95% 91% 89%
Ceftriaxone 96% 89% 91% Ceftriaxone 95% 91% 89%
Cefaclor 96% 89% 82% Cefaclor 94% 91% 87%
Cotrimoxazole 63% 50% 57% Nitrofurantoin 89% 86% 91%
Ciprofloxacin 93% 90% 92% Nalidixic acid 74% 72% 87%
Nitrofurantoin 79% 80% 87% Ciprofloxacin 89% 91% 89%
Nalidixic acid 81% 75% 68% Cefepime - 91% 87%
Cefepime - 91% 86% Meropenem/Imipenem - 100% 100%
Meropenem/Imipenem - 98% 100% Tazo/Piperacillan - 100% 100%
Tazo/Piperacillan - 99% 99% Ticarcillin/Clavulanate - 100% 100%
Ticarcillin/Clavulanate 100% 100% 100%     







632 isolates 356 isolates
Piperacillin 76% 81% Gentamicin 85% 78%
Tazobactam/Piperacillin 100% 99% Amikacin 86% 83%
Imipenem/Meropenem 94% 91% Chloramphenicol 64% 55%
Ceftazidime 74% 75% Cefuroxime 87% 72%
Ceftriaxone 74% 74% Ceftazidime 92% 82%
Gentamicin 72% 58% Ceftriaxone 92% 82%
Amikacin 86% 84% Cefaclor 87% 72%
Ticarcillin – Clavulanate 100% - Nitrofurantoin 89% 91%
Ciprofloxacin 81% 78% Nalidixic acid 72% 64%
Cefepime 74% 62% Ciprofloxacin 80% 86%
   Cefepime 92% 89%
   Meropenem/Imipenem - 99%
   Tazo/Piperacillan - 98%
 Ticarcillin/Clavulanate - 99%
SALMONELLA SPP.  
Antibiotic
221 ISOLATES  
Percentage susceptible  
Ampicillin   58%  
Cotrimoxazole   45%  
Chloramphenicol   55%  
Ciprofloxacin   100%  
Cetriaxone   93%  
NEW DEVELOPMENTS ON THE PRESCRIPTION
ADMINISTRATION CHART
The Pharmacy Department is continuously looking at ways and means of improving the quality of care provided to the patient. As you all know and must have
used, there is the In-patient Medication Order Sheet (Treatment Sheet) to prescribe all medications for patients admitted or undergoing surgery in the hospital.
The Pharmacy Department in consultation with various clinical departments and approved by the Pharmacy and Therapeutics Committee has revised the
Treatment Sheet. The new Treatment Sheet will be operational as from 1st January 2007.
The new Treatment Sheet is in two colours now; the first four pages in yellow (specific for antibiotic prescribing) and the rest in white and it contains:
PAGE 1 (Yellow)
Patient details, drug allergies and lab parameters important for antimicrobial prescribing such as culture and sensitivity, serum creatnine levels, liver function and
dialysis, section to indicate if antibiotic is for surgical prophylaxis, section to indicate if antibiotics are for empiric therapy or for documented infection
For prescribing Prophylactic doses of antibiotics
PAGE 2 – 3 (Yellow)
For prescribing Therapeutic/Empiric regimens of antibiotics
PAGE 4 (Yellow)
Principles of anti-microbial prescribing
All areas of the Antibiotic Order sheet must be fully completed before Pharmacy will dispense Antibiotics
Antibiotics orders will lapse after 24 hours for Prophylactic Orders, after 72 hours for Empiric Orders and after 7days for Therapeutic Orders unless
renewed.
A list of special Antibiotics which must be only prescribed after consultation with or endorsement by the primary physician.
The Request form for C/S must be sent before Antibiotics have been initiated and with appropriate clinical history and history of antibiotics filled.
PAGE 5 (White)
For prescribing Once only, Pre-medication and PRN medication
PAGE 6 – 8 (White)
For prescribing Regular medications section for all other drugs
PAGE 9 (White)
Discharge prescription. Please note it is legally required to record the name of the patient in the name section of the discharge prescription and the doctors
name and signature.
PAGE 10 (White)




NB: It is mandatory to provide all the requested information before the Pharmacy Department can dispense.
